Page 208 - 2021_03-Haematologica-web
P. 208
V. Wiebking et al.
A
B
Figure 4. Antileukemic activity of genome-edited chimeric antigen receptor T cells in vivo. (A) Bioluminescence imaging of Nalm6 xenografts in NSG mice treated with genome-edited CD19-specific chimeric antigen receptor (CAR) T cells (1x106) that were manufactured from aβ-TCR+ T cells. The experiment was repeated at the dose level of 5x106 cells per mouse with comparable outcome. (B) Kaplan-Meier survival plot of mice treated with control T cells or CAR T cells. Asterisks indicate levels of significance of the CAR T-cell group compared to the respective control group (mock) of the same cell dose using log-rank tests. CAR: chimeric antigen receptor.
854
haematologica | 2021; 106(3)
